StockData
Inhibrx Biosciences, Inc. logo

Inhibrx Biosciences, Inc. (INBX) stock

INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 1/30
$69.06−5.12 (-6.90%)

Close on Nov 18, 2026Market cap $1.02BP/E –Yield –

Inhibrx Biosciences revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Inhibrx Biosciences's revenue for the twelve months ending Dec 31, 2025 was $1.30M, up 550.0% year over year. For fiscal 2025 it was $1.30M, up 550.0% from the year before. The highest annual figure on record is $13.21M in fiscal 2019.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.30M+550.0%
FY2024Dec 31, 2024$200.00K-88.9%
FY2023Dec 31, 2023$1.80M-17.9%
FY2022Dec 31, 2022$2.19M-69.7%
FY2021Dec 31, 2021$7.23M-43.9%
FY2020Dec 31, 2020$12.89M-2.4%
FY2019Dec 31, 2019$13.21M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$2.00M+53.8%
Q2 FY2026Jun 30, 2026$0–
Q4 FY2025Dec 31, 2025$0-100.0%
Q3 FY2025Sep 30, 2025$0–
Q2 FY2025Jun 30, 2025$1.30M+1200.0%
Q1 FY2025Mar 31, 2025$0–
Q4 FY2024Dec 31, 2024$100.00K-93.9%
Q3 FY2024Sep 30, 2024$0-100.0%
Q2 FY2024Jun 30, 2024$100.00K+233.3%
Q1 FY2024Mar 31, 2024$0-100.0%
Q4 FY2023Dec 31, 2023$1.63M+496.4%
Q3 FY2023Sep 30, 2023$119.00K-57.2%
Q2 FY2023Jun 30, 2023$30.00K-95.8%
Q1 FY2023Mar 31, 2023$17.00K-98.2%
Q4 FY2022Dec 31, 2022$274.00K-90.4%
Q3 FY2022Sep 30, 2022$278.00K-89.0%
Q2 FY2022Jun 30, 2022$711.00K-25.5%
Q1 FY2022Mar 31, 2022$929.00K+4.5%
Q4 FY2021Dec 31, 2021$2.86M+2.9%
Q3 FY2021Sep 30, 2021$2.53M-57.1%
Q2 FY2021Jun 30, 2021$954.00K-71.4%
Q1 FY2021Mar 31, 2021$889.00K+1.9%
Q4 FY2020Dec 31, 2020$2.78M+955.5%
Q3 FY2020Sep 30, 2020$5.90M+384.1%
Q2 FY2020Jun 30, 2020$3.34M–
Q1 FY2020Mar 31, 2020$872.00K–
Q4 FY2019Dec 31, 2019$263.00K–
Q3 FY2019Sep 30, 2019$1.22M–

More Inhibrx Biosciences figures

See a number that looks wrong?